查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654664

全球胆固醇检测产品市场 - 2025 至 2033 年

Global Cholesterol Testing Products Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球胆固醇检测产品市场规模达到 198.5 亿美元，预计到 2033 年将达到 422.5 亿美元，2025-2033 年预测期间的复合年增长率为 8.8%。

胆固醇测试是测量血液中胆固醇水平的重要诊断程序，有助于评估心臟病、中风和动脉粥状硬化等心血管疾病的风险。胆固醇检测产品是测量血液中胆固醇水平的重要工具，在检测、预防和管理心血管疾病方面发挥着至关重要的作用。

这些产品形式多样，从传统的实验室试剂盒到更方便的即时诊断设备和家庭检测试剂盒，让个人和医疗保健提供者都可以轻鬆监测胆固醇水平。透过测量 LDL（坏胆固醇）和 HDL（好胆固醇）等关键成分，这些产品有助于评估心臟病的风险并指导治疗计划以改善心臟健康。随着人们对心臟健康认识的不断增强，这些胆固醇测试产品的需求也在增加，以支持主动和预防性护理。

市场动态：

驱动因素与约束因素

心血管疾病发生率上升

受心血管疾病（CVD）影响的人数不断增加是推动胆固醇检测需求的关键因素。心臟病和中风已成为全球主要的死亡原因，人们越来越意识到控制胆固醇水平对于维持心臟健康的重要性。高胆固醇是导致这些疾病的主要原因，因此定期进行胆固醇检测对于医疗保健专业人员和想要预防严重健康问题的个人来说都是重要的一步。

随着越来越多的人被诊断出患有高血压、肥胖症和糖尿病等相关疾病，对可靠且易于使用的胆固醇检测工具的需求也越来越大。人们对早期检测的认识和关注度不断提高，预计将推动胆固醇检测市场的发展，更多的人将积极寻求监测和管理胆固醇的方法，以降低心血管疾病的风险。

治疗费用高昂

先进胆固醇检测设备的高成本可能会严重阻碍胆固醇检测产品市场的成长，尤其是在低收入地区或较小的医疗保健提供者。许多先进的胆固醇检测设备，例如专业实验室使用的设备或专门的临床检测设备，需要大量的前期投资。这些设备通常具有高昂的维护成本、正确使用的训练要求以及定期校准以确保准确性的需要。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 研发进度
    • 限制
      • 治疗费用高昂
    • 机会
    • 影响分析

第五章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 专利分析
  • 监管分析
  • SWOT 分析
  • 未满足的需求

第 6 章：按产品

  • 装置
  • 测试套件
  • 其他的

第 7 章：按测试类型

  • 总胆固醇测试
  • 低密度脂蛋白（LDL）胆固醇测试
  • 高密度脂蛋白（HDL）胆固醇测试
  • 三酸甘油酯测试
  • 其他的

第 8 章：按应用

  • 心血管疾病
  • 糖尿病
  • 肥胖
  • 高血脂症
  • 其他的

第 9 章：按最终用户

  • 医院
  • 诊断中心
  • 家庭医疗保健
  • 研究实验室

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Abbott Laboratories
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • F. Hoffmann-La Roche AG
  • Siemens Healthineers GmbH
  • ACON Laboratories Inc.
  • Lepu Medical Technology (Beijing)Co., Ltd.
  • SD Biosensor, INC.
  • Recombigen Laboratories Pvt. Ltd
  • Assure Tech (Hangzhou) Co., Ltd.
  • VP Healthcare
  • SG Diagnostics
  • Similar data will be provided for each market player.
  • Processa 製药公司
    • 管道产品描述
    • 产品关键绩效指标 (KPI)
    • 主要活动
    • 市场进入时间表
    • 产品渗透率
    • 销售估计和预测
  • Vanda 製药公司
  • Renexxion 爱尔兰有限公司
  • Aclipse治疗公司
  • 将为每个市场参与者提供类似的资料。

第 13 章：附录

简介目录
Product Code: MD4219

The global cholesterol testing products market reached US$ 19.85 billion in 2024 and is expected to reach US$ 42.25 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.

Cholesterol testing is a vital diagnostic procedure used to measure the levels of cholesterol in the blood, helping to assess the risk of cardiovascular diseases such as heart disease, stroke, and atherosclerosis. Cholesterol testing products are important tools used to measure cholesterol levels in the blood, playing a vital role in detecting, preventing, and managing cardiovascular diseases.

These products come in various forms, from traditional lab-based kits to more convenient point-of-care devices and at-home testing kits, giving both individuals and healthcare providers easy access to monitor cholesterol levels. By measuring key components like LDL (bad cholesterol) and HDL (good cholesterol), these products help evaluate the risk of heart disease and guide treatment plans to improve heart health. With the growing awareness of heart health, the demand for these cholesterol testing products is increasing, supporting proactive and preventive care.

Market Dynamics: Drivers & Restraints

Rising Incidence of Cardiovascular Diseases

The growing number of people affected by cardiovascular diseases (CVDs) is a key factor driving the demand for cholesterol testing. With heart disease and strokes being the leading causes of death around the world, there's a rising awareness about how crucial it is to keep cholesterol levels in check to maintain heart health. High cholesterol is a major contributor to these conditions, making regular cholesterol testing an important step for both healthcare professionals and individuals who want to prevent serious health issues.

As more people are diagnosed with related conditions like high blood pressure, obesity, and diabetes there's a greater need for reliable and easy-to-use cholesterol testing tools. This growing awareness and focus on early detection are expected to boost the cholesterol testing market, with more people actively seeking ways to monitor and manage their cholesterol to lower the risk of cardiovascular problems.

High Costs of Treatment

The high cost of advanced cholesterol testing devices can significantly hinder the growth of the cholesterol testing products market, especially in low-income regions or for smaller healthcare providers. Many advanced cholesterol testing devices, such as those used in professional labs or specialized point-of-care testing equipment, require significant upfront investment. These devices often come with high maintenance costs, training requirements for proper usage, and the need for regular calibration to ensure accuracy.

Segment Analysis

The global cholesterol testing products market is segmented based on procedure type, device type, surgery type, indication, end-user, and region.

Treatment:

Devices segment is expected to dominate the global cholesterol testing products market share

The devices segment is expected to dominate the cholesterol testing products market due to a combination of technological advancements, growing consumer demand for at-home testing, and the increasing focus on preventive healthcare. With innovations in point-of-care testing devices and self-monitoring kits, cholesterol testing has become more accurate, accessible, and convenient, allowing individuals to monitor their cholesterol levels from the comfort of their homes.

The integration of these devices with mobile apps and digital health platforms further enhances their appeal by enabling real-time tracking and personalized health insights. As the shift toward proactive health management continues, cholesterol testing devices are becoming essential tools for both healthcare professionals and consumers, driving widespread adoption and market growth. Their ability to provide quick, reliable results at an affordable cost positions them as the leading solution in the market.

Geographical Analysis

North America is expected to hold a significant position in the global cholesterol testing products market share

North America is leading the cholesterol testing products market due to high levels of awareness about heart health, and a strong emphasis on preventive care. The region benefits from well-established healthcare systems, widespread access to cutting-edge medical devices, and a growing focus on early detection and management of cardiovascular diseases. In addition, both the U.S. and Canada have robust health insurance systems that often cover the cost of cholesterol testing, making it more accessible to the general population.

The increasing prevalence of high cholesterol, coupled with rising healthcare awareness campaigns, has driven the adoption of cholesterol testing products, further solidifying North America's dominance in the market. For instance, according to the Tebra Inc. in 2024, approximately 71 million Americans have high cholesterol, and although there are many potential causes, one key factor is that certain habits can raise cholesterol levels without people even realizing it. Furthermore, the integration of innovative technologies like point-of-care testing devices and digital health solutions has contributed to the region's leadership in cholesterol monitoring.

Competitive Landscape

The major global players in the cholesterol testing products market include Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers GmbH, ACON Laboratories Inc., Lepu Medical Technology (Beijing)Co., Ltd., SD Biosensor, INC., Recombigen Laboratories Pvt. Ltd, Assure Tech (Hangzhou) Co., Ltd., V.P. Healthcare and SG Diagnostics among others.

Key Developments

  • In August 2024, AstraZeneca's Imfinzi (durvalumab) received approval in the United States for use in combination with chemotherapy to treat adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
  • In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have a BRAF V600E mutation, as identified by an FDA-approved test. This approval provides a new personalized treatment option for patients with this specific mutation in their cancer.
  • In August 2023, Eli Lilly and Company announced the topline results from the LIBRETTO-431 study, which evaluated Retevmo (selpercatinib) against platinum-based chemotherapy plus pemetrexed as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC).

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Cholesterol Testing Products Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancements in Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Product

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Test Kits
  • 6.4. Others

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 7.1.2. Market Attractiveness Index, By Test Type
  • 7.2. Total Cholesterol Tests*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Low Density-Lipoprotein (LDL) Cholesterol Tests
  • 7.4. High-Density Lipoprotein (HDL) Cholesterol Tests
  • 7.5. Triglycerides Tests
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular Diseases*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diabetes
  • 8.4. Obesity
  • 8.5. Hyperlipidemia
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Home Healthcare
  • 9.5. Research Laboratories

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. F. Hoffmann-La Roche AG
  • 12.3. Siemens Healthineers GmbH
  • 12.4. ACON Laboratories Inc.
  • 12.5. Lepu Medical Technology (Beijing)Co., Ltd.
  • 12.6. SD Biosensor, INC.
  • 12.7. Recombigen Laboratories Pvt. Ltd
  • 12.8. Assure Tech (Hangzhou) Co., Ltd.
  • 12.9. V.P. Healthcare
  • 12.10. SG Diagnostics
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. Processa Pharmaceuticals, Inc.*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. Vanda Pharmaceuticals Inc.
  • 12.13. Renexxion Ireland Limited
  • 12.14. Aclipse Therapeutics
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us